search
Back to results

Influence of Probiotics Administration Before Liver Resection in Liver Disease (LIPROCES)

Primary Purpose

Liver Fibrosis, Liver Cirrhosis, Permeability; Increased

Status
Completed
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
Probiotic
Placebo
Sponsored by
University Hospital, Rouen
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Liver Fibrosis focused on measuring Endotoxemia, Probiotic, Leaky gut, Gut permeability, Liver cirrhosis, Liver fibrosis, Hepatocellular carcinoma

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Agreement signed by the patient
  • Diagnosis of HCC confirmed
  • Diagnosis of liver disease (score F3 or F4) confirmed
  • Indication of surgical resection confirmed and validated by a specialist multidisciplinary assessment meeting of gastrointestinal oncology
  • Patient operable (no indication against anaesthesiological)
  • Resectable tumor lesion (surgical expertise)
  • Laboratory tests and endoscopy: No suspicion of severe portal hypertension with bleeding risk

Exclusion Criteria:

  • Patient not willing, at risk of default of compliance, or patient can not be monitored regularly
  • Antibiotic extended or terminated for less than 1 month, may limit the effects of taking probiotics.
  • Inflammatory Bowel Disease, which could skew the results expected by taking probiotics results.

Sites / Locations

  • University Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Placebo Comparator

Active Comparator

Arm Label

Placebo of Probiotics

Probiotics- Lactibiane Tolerance

Arm Description

Placebo: Composition: Each capsule contains 560 mg: 459 mg of corn starch 6 mg of magnesium stearate Dosage: 2 capsules / day, in the morning at sunrise, one at bedtime. Methods of administration: Oral. Duration of treatment: 14 days

Active substance mixture of lactic 10% Bifidobacterium lactis LA 303, 10% Lactobacillus acidophilus LA 201, LA 40% Lactobacillus plantarum 301, 20% Lactobacillus salivarius LA 302, LA 20% Bifidobacterium lactis 304 Dosage: 10 X 10^9 probiotic / capsule Composition: One capsule of 560 mg contains Lactibiane tolerance: 345 mg of corn starch 114 mg premix lactic 6 mg of magnesium stearate Excipients: magnesium stearate Method of administration: Oral Dosage: 2 capsules per day for 14 days in two doses: one capsule at sunrise, one capsule at bedtime;

Outcomes

Primary Outcome Measures

Area under the plasma concentration versus time curve (AUC) of endotoxins circulating levels

Secondary Outcome Measures

Full Information

First Posted
July 3, 2013
Last Updated
May 14, 2018
Sponsor
University Hospital, Rouen
search

1. Study Identification

Unique Protocol Identification Number
NCT02021253
Brief Title
Influence of Probiotics Administration Before Liver Resection in Liver Disease
Acronym
LIPROCES
Official Title
Circulating Endotoxemia After Liver Resection for Hepatocellular Carcinoma in Liver Disease - Influence of Preoperative Administration of Probiotics
Study Type
Interventional

2. Study Status

Record Verification Date
May 2018
Overall Recruitment Status
Completed
Study Start Date
April 2013 (undefined)
Primary Completion Date
April 12, 2018 (Actual)
Study Completion Date
April 12, 2018 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University Hospital, Rouen

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Surgical resection is one of the curative treatment modalities for HCC. Limits are postoperative septic and liver functional complications related to an increase in bacterial translocation and systemic endotoxemia. Bacterial translocation is a passage of bacteria and bacterial degradation products from the intestine to the portal circulation. The endotoxemia secondary to bacterial translocation, stimulates endothelial production of nitric oxide (NO). NO is also a potent inducer of membrane instability, responsible for an increase in the permeability of the vascular endothelium and intestinal mucosa, possibly contributing to a worsening of bacterial translocation. Probiotics are live microorganisms which when administered in adequate amounts, provide a health benefit on the host ((Health and Nutritional Properties of Probiotics in Food Including Powder Milk with Live Lactic Acid Bacteria - Cordoba Argentina October 2001). Data from experimental and clinical literature show a significant effect of probiotics on the improvement of liver function and a decrease in infectious complications in patients with chronic liver disease. The proposed study would evaluate the effect preventive and therapeutic in a population of surgical patients, in whom the intestinal portal and hepatic inflammation promotes postoperative complications.
Detailed Description
The aim of this study is to evaluate the effect of the administration of probiotics on intestinal barrier function in patients with chronic liver disease (fibrosis stage F3 or F4) operated for hepatocellular carcinoma. After hepatectomy, kinetic of endotoxemia have been studied previously and the evolution will be summarized by the area under the plasma concentration versus time curve (AUC) of circulating endotoxin levels measured before surgery and at 5 different times analysis after hepatectomy. At 12 hours, portal hypertension and its consequences on gut permeability (impaired barrier function, bacterial translocation) are highest with peak of circulating endotoxins. The decreasing of endotoxemia curve is observed between the 2nd and 3rd day (end of liver regeneration and early liver architectural reorganization). On the 5th day, persist measurable but not deleterious to liver restructured and theoretically functional rates. Then the main criterion to demonstrate the effectiveness of a diet enriched with probiotics is the AUC of circulating levels of endotoxins ((pg/ml) using the Limulus amebocyte lysate (LAL) assay) observed for each patient. Endotoxin levels were analysed on samples of peripheral blood. The two arms of equal size will be considered significantly different when compared to the AUC of circulating levels of endotoxin if the null hypothesis (AUC is the same for both arms) is rejected in favor of the alternative hypothesis (AUC differs between the two arms - Wilcoxon test) In order to estimate the sample size to distinguish between the two hypotheses with sufficient power, the median AUC in arm without probiotics be used to form two groups of patients in each arm. Thus, half of the patients without probiotics have a higher median AUC arms. Then, this proportion may be compared to the proportion of patients with probiotics have an AUC greater than the median of the group without probiotics. The secondary endpoints are: Evaluation of systemic inflammation by assay of inflammatory cytokines IL-2, IL-4, IL-6, IL-8, IL-10, GM-CSF, IFNa, TNFa CRP Leukocyte count The post-operative liver function monitored in the usual manner Standard Liver function tests between J1 and J5 (Bilirubin, prothrombin, ammonia) Indocyanine green clearance with measuring retention rates at 15 minutes between J1 and J3 Monitoring of overall postoperative complications and specifically liver failure and infectious complications at 3 months.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Liver Fibrosis, Liver Cirrhosis, Permeability; Increased, Hepatocellular Carcinoma
Keywords
Endotoxemia, Probiotic, Leaky gut, Gut permeability, Liver cirrhosis, Liver fibrosis, Hepatocellular carcinoma

7. Study Design

Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
64 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Placebo of Probiotics
Arm Type
Placebo Comparator
Arm Description
Placebo: Composition: Each capsule contains 560 mg: 459 mg of corn starch 6 mg of magnesium stearate Dosage: 2 capsules / day, in the morning at sunrise, one at bedtime. Methods of administration: Oral. Duration of treatment: 14 days
Arm Title
Probiotics- Lactibiane Tolerance
Arm Type
Active Comparator
Arm Description
Active substance mixture of lactic 10% Bifidobacterium lactis LA 303, 10% Lactobacillus acidophilus LA 201, LA 40% Lactobacillus plantarum 301, 20% Lactobacillus salivarius LA 302, LA 20% Bifidobacterium lactis 304 Dosage: 10 X 10^9 probiotic / capsule Composition: One capsule of 560 mg contains Lactibiane tolerance: 345 mg of corn starch 114 mg premix lactic 6 mg of magnesium stearate Excipients: magnesium stearate Method of administration: Oral Dosage: 2 capsules per day for 14 days in two doses: one capsule at sunrise, one capsule at bedtime;
Intervention Type
Dietary Supplement
Intervention Name(s)
Probiotic
Other Intervention Name(s)
Lactibiane TOLERANCE (PILeJe) 5 probiotics association
Intervention Description
Lactibiane TOLERANCE vs Placebo
Intervention Type
Dietary Supplement
Intervention Name(s)
Placebo
Primary Outcome Measure Information:
Title
Area under the plasma concentration versus time curve (AUC) of endotoxins circulating levels
Time Frame
-12, 3, 12,24, 72, 120 hours at time of surgery

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Agreement signed by the patient Diagnosis of HCC confirmed Diagnosis of liver disease (score F3 or F4) confirmed Indication of surgical resection confirmed and validated by a specialist multidisciplinary assessment meeting of gastrointestinal oncology Patient operable (no indication against anaesthesiological) Resectable tumor lesion (surgical expertise) Laboratory tests and endoscopy: No suspicion of severe portal hypertension with bleeding risk Exclusion Criteria: Patient not willing, at risk of default of compliance, or patient can not be monitored regularly Antibiotic extended or terminated for less than 1 month, may limit the effects of taking probiotics. Inflammatory Bowel Disease, which could skew the results expected by taking probiotics results.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Lilian Schwarz, MD
Organizational Affiliation
DRCI Rouen
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Emmanuel Huet, MD
Organizational Affiliation
DRCI Rouen
Official's Role
Principal Investigator
Facility Information:
Facility Name
University Hospital
City
Rouen
State/Province
Haute Normandie
ZIP/Postal Code
76000
Country
France

12. IPD Sharing Statement

Citations:
PubMed Identifier
34837121
Citation
Roussel E, Brasse-Lagnel C, Tuech JJ, Montialoux H, Papet E, Tortajada P, Bekri S, Schwarz L. Influence of Probiotics Administration Before Liver Resection in Patients with Liver Disease: A Randomized Controlled Trial. World J Surg. 2022 Mar;46(3):656-665. doi: 10.1007/s00268-021-06388-7. Epub 2021 Nov 26. Erratum In: World J Surg. 2021 Dec 15;:
Results Reference
derived

Learn more about this trial

Influence of Probiotics Administration Before Liver Resection in Liver Disease

We'll reach out to this number within 24 hrs